On a quest to treat newly diagnosed lymphoma patients, Roche teases positive pivotal data

A couple of years ago, as generics were eating into the sales of its top three cancer drugs, Roche snagged an early approval for its antibody-drug conjugate Polivy in previously treated diffuse large B-cell lymphoma (DLBCL) patients. Now, the company’s looking to position the drug as a first-line treatment — and it says it has the topline data from a large, international study to back it up.